SEC23A Inhibitors
SEC23A, a crucial component of the COPII vesicle formation pathway, plays a pivotal role in mediating the transport of proteins from the endoplasmic reticulum (ER) to the Golgi apparatus. The inhibitors selected above employ diverse mechanisms to either directly target SEC23A or indirectly influence its function by impacting related signaling pathways. Sar1 GTPase Inhibitor and SecinH3 are direct inhibitors that disrupt the activation of Sar1, a small GTPase crucial for COPII vesicle budding. Inhibition of Sar1 impacts the early steps of COPII vesicle formation, leading to impaired cargo selection and transport regulated by SEC23A. Several compounds, such as I-BET151 and Brefeldin A, indirectly modulate SEC23A by influencing transcriptional regulation and small GTPase function, respectively. I-BET151 alters chromatin landscape, affecting the expression of COPII components, including SEC23A, while Brefeldin A inhibits ADP-ribosylation of small GTPases, indirectly impacting SEC23A-mediated vesicular transport. Navitoclax and Reticuline indirectly influence SEC23A by affecting ER stress response pathways and the mTORC1 pathway, respectively. These compounds induce ER stress or inhibit mTORC1, leading to downstream effects that impact SEC23A function and disrupt vesicular trafficking.
Other inhibitors, such as MLN4924 and Monensin, indirectly modulate SEC23A through the neddylation pathway and the endocytic pathway, respectively. MLN4924 disrupts the neddylation of cullin-RING ligases, impacting the turnover of proteins involved in COPII vesicle formation. Monensin alters endosomal acidification, influencing vesicle trafficking and secretion pathways that indirectly affect SEC23A-mediated cargo transport. Y-27632 and Cerulenin indirectly impact SEC23A through the RhoA/ROCK pathway and fatty acid synthesis, respectively, altering cellular processes related to COPII vesicle formation. Pyrvinium Pamoate and Eeyarestatin I showcase indirect modulation of SEC23A through Wnt signaling inhibition and ER-associated protein degradation (ERAD), respectively. Pyrvinium Pamoate targets the β-catenin destruction complex, influencing pathways related to COPII vesicle formation. Eeyarestatin I disrupts ERAD, leading to ER stress and impacting SEC23A-mediated vesicle formation. In summary, SEC23A inhibitors, whether direct or indirect, offer valuable tools to dissect and manipulate cellular processes dependent on COPII vesicle formation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SecinH3 | 853625-60-2 | sc-203260 | 5 mg | $278.00 | 6 | |
A specific inhibitor of small GTPases, including Sar1, which indirectly influences SEC23A. SecinH3 disrupts the activation of small GTPases, leading to impaired COPII vesicle formation. The inhibition of this critical step impacts SEC23A function, hindering the ER-to-Golgi transport of cargo proteins. | ||||||
I-BET 151 Hydrochloride | 1300031-49-5 (non HCl Salt) | sc-391115 | 10 mg | $450.00 | 2 | |
A BET bromodomain inhibitor that indirectly modulates SEC23A by influencing the transcriptional regulation of COPII components. I-BET151 alters the chromatin landscape, affecting the expression of genes involved in COPII vesicle formation, including SEC23A. This indirect modulation can lead to impaired COPII vesicle assembly and subsequent disruption of ER-to-Golgi transport. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
A fungal metabolite that disrupts protein transport from the ER to the Golgi apparatus by inhibiting ADP-ribosylation of small GTPases, including Sar1. Brefeldin A indirectly impacts SEC23A by preventing the formation of functional COPII vesicles, leading to the mislocalization of cargo proteins and disrupting normal cellular processes reliant on SEC23A-mediated vesicular transport. | ||||||
ABT 263 | 923564-51-6 | sc-207241 | 5 mg | $245.00 | 16 | |
An inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-xL, and Bcl-w, which indirectly influences SEC23A by affecting ER stress response pathways. Navitoclax induces ER stress, leading to the activation of the unfolded protein response (UPR) and the downregulation of COPII components, including SEC23A. This indirect modulation disrupts ER-to-Golgi transport and cellular homeostasis regulated by SEC23A. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
An NEDD8-activating enzyme (NAE) inhibitor that indirectly influences SEC23A through the inhibition of cullin-RING ligases (CRLs). MLN4924 disrupts the neddylation pathway, leading to the stabilization of CRL substrates. This indirect modulation affects the turnover of proteins involved in COPII vesicle formation, including SEC23A, and subsequently impairs ER-to-Golgi transport. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
An ionophore antibiotic that indirectly modulates SEC23A by impacting protein trafficking through the endocytic pathway. Monensin disrupts the acidification of endosomes, leading to alterations in vesicle trafficking and secretion pathways, indirectly affecting SEC23A-mediated cargo transport from the ER to the Golgi apparatus. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A selective inhibitor of Rho-associated protein kinase (ROCK), which indirectly influences SEC23A through the RhoA/ROCK pathway. Y-27632 inhibits ROCK, affecting actin cytoskeleton dynamics and vesicular transport. This indirect modulation can impact SEC23A function, disrupting the COPII vesicle formation pathway and altering ER-to-Golgi transport of cargo proteins. | ||||||
Cerulenin (synthetic) | 17397-89-6 | sc-200827 sc-200827A sc-200827B | 5 mg 10 mg 50 mg | $161.00 $312.00 $1210.00 | 9 | |
A fungal metabolite that indirectly influences SEC23A through the inhibition of fatty acid synthesis. Cerulenin inhibits fatty acid synthase (FASN), leading to alterations in membrane lipid composition. This indirect modulation can impact the biogenesis of COPII vesicles and subsequently disrupt the ER-to-Golgi transport pathway regulated by SEC23A. | ||||||
Pyrvinium Pamoate | 3546-41-6 | sc-476920A sc-476920 | 250 mg 500 mg | $228.00 $422.00 | ||
An anthelmintic drug that indirectly modulates SEC23A through the inhibition of Wnt signaling. Pyrvinium Pamoate targets the β-catenin destruction complex, leading to the downregulation of Wnt signaling. This indirect modulation can affect SEC23A function by influencing cellular pathways related to COPII vesicle formation, disrupting ER-to-Golgi transport and cargo trafficking processes. | ||||||
Eeyarestatin I | 412960-54-4 | sc-358130B sc-358130 sc-358130A sc-358130C sc-358130D sc-358130E | 5 mg 10 mg 25 mg 50 mg 100 mg 500 mg | $114.00 $203.00 $354.00 $697.00 $1363.00 $5836.00 | 12 | |
A compound that indirectly influences SEC23A by affecting ER-associated protein degradation (ERAD). Eeyarestatin I disrupts ERAD, leading to the accumulation of misfolded proteins and ER stress. This indirect modulation can impact SEC23A function by interfering with the ER quality control system, ultimately influencing COPII vesicle formation and the ER-to-Golgi transport pathway. | ||||||